A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.
Also called NCT02914665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 308 participants
- Sponsor
- Stealth BioTherapeutics Inc.
- Registry
-
NCT02914665 -
2016-000126-19
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Bulgaria, France, Hungary, Latvia, Netherlands, Poland, Serbia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02914665. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-20 (actual); primary completion 2017-11-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- Condition
- Heart Failure
- Intervention (Drug)
- elamipretide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Stealth BioTherapeutics Inc.
Record details
- Record id
cardio:ct-nct02914665- Content hash
651293855fc78e4da969be0ed81edadd0ae6e6b371212faa9498cdfa1cfd0699